Abstract：
This article presents an overview of treatment regimens of drugs containing antivascular endothelial growth factor for the treatment of neovascular form of age-related macular degeneration. Currently, drugs containing antivascular endothelial growth factor are the only effective treatment for this chronic and progressive disease. The treatment regimens for this disease in the last two decades have seen a shift from a simple endeavor to stabilize the disease to achieving maximum improvement of visual acuity and its maintenance, with improvement of the patient\'s quality of life and a minimal treatment burden on patients and their families. Other goals of the alternative dosing regimens that have replaced the original fixed regimens were greater individualization of the dosing regimen, better patient cooperation, saving financial costs and reducing the burden on application centers. Age-related macular degeneration, whether dry form or wet form, represents a serious health and socioeconomic problem, as the disease is one of the most common causes of severe and irreversible central visual acuity disorders up to the degree of practical blindness of one or both eyes in people over 50 years of age in developed industrialized countries. The most important issue is to ensure early diagnosis of this disease, followed by prompt and continuous treatment with an individualized proactive treatment regimen, with the aim of stabilizing and improving anatomical and functional results.
摘要：
本文概述了含有抗血管内皮生长因子的药物用于治疗年龄相关性黄斑变性的新生血管形式的治疗方案。目前,含有抗血管内皮生长因子的药物是这种慢性和进行性疾病的唯一有效治疗方法。在过去的二十年中，这种疾病的治疗方案已经从简单的稳定疾病的努力转变为最大程度地改善视敏度及其维持。改善患者的生活质量，减轻患者及其家属的治疗负担。替代给药方案取代了原来的固定给药方案的其他目标是给药方案的更大个性化。更好的耐心合作，节省财务成本，减轻应用中心的负担。年龄相关性黄斑变性,无论是干形式还是湿形式，代表着严重的健康和社会经济问题，由于这种疾病是最常见的原因之一严重和不可逆的中枢神经系统的视力障碍，在发达的工业化国家的50岁以上的人的一只或两只眼睛的实际失明的程度。最重要的问题是确保这种疾病的早期诊断，然后是快速和连续的治疗，并采用个性化的主动治疗方案，目的是稳定和改善解剖和功能结果。
